Fundz

Who to call at Ascidian Therapeutics, and when

Fundz watches for the moments Ascidian Therapeutics starts buying, and tells you who to reach.

  • An alert the day Ascidian Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ascidian Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Ascidian and Eli Lilly enter a partnership worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases.

Jun 03, 2026

Contract Type

partnership

BostonBiotechnologyHealth CareMedicalTherapeutics

Description

Ascidian Therapeutics has signed a research collaboration with Eli Lilly, which could be worth up to $1.9 billion. This partnership combines Ascidian’s RNA exon editing technology with Lilly’s expertise in genetic medicines and renal disease to advance therapies for genetic kidney diseases.

Company Information

Company

Ascidian Therapeutics

Location

Boston, Massachusetts, United States

About

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Related People

Murray
Likely contact at this company
••••••••@••••••••

See Murray's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Ascidian Therapeutics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Ascidian Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.